abametapir · Lnhc · NDA 206966
Xeglyze
Earliest generic entry, as listed
17 Dec 2034
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 10292389.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10292389 | product, use U-2863 | 17 Dec 2034 |
| US 7812163 | product, use U-2863 | 28 Oct 2026 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 206966 · 001 · RLD · discontinued | lotion, topical | 0.74% | 17 Dec 2034 |